SuppreMol is a biotechnology company developing treatment of autoimmune diseases leading to the cure of such disorders.
SuppreMol is a privately held biotechnology company that pioneers a novel approach for the treatment of autoimmune diseases which could lead to the cure of these disorders instead of merely treating their symptoms.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
May 21, 2013 | Series D | €9.50M | 1 | — | — | Detail |
Dec 17, 2010 | Series C | €15.50M | 2 | — | — | Detail |
Jul 15, 2008 | Series B | €15.70M | 1 | — | — | Detail |
May 24, 2006 | Series A | $5.15M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
FCP Biotech Holding | — | Series D |
Bayern Kapital | — | Series C |